Table 4.
Incidence rate of total SREs by line of anti-MM therapy among patients initiating anti-MM therapy.
| Cumulative follow-up time (median follow-up: 25.7 months) |
Line 1 |
Line 2 |
Line 3 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients with SREs, n | SREs, n | Incidence rate per 100 PYs | Patients with SREs, n | SREs, n | Incidence rate per 100 PYs | Patients with SREs, n | SREs, n | Incidence rate per 100 PYs | |
| 3 months | 41 | 59 | 81.11 | 29 | 43 | 117.88 | 17 | 28 | 150.29 |
| 12 months | 65 | 127 | 70.44 | 41 | 87 | 94.25 | 23 | 55 | 130.72 |
| 24 months | 70 | 140 | 57.49 | 43 | 94 | 82.35 | 23 | 57 | 116.55 |
MM, multiple, myeloma; PYs, person-years; SREs, skeletal-related events.